Anticancer composition for treating solid tumors and use thereof

A composition and technology for solid tumors, applied in drug combinations, medical preparations containing active ingredients, antineoplastic drugs, etc.

Active Publication Date: 2021-04-30
DASEN BIOLOGICAL PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Crude collagenase also contains other hydrolytic enzymes, so it is prone to other unexpected side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer composition for treating solid tumors and use thereof
  • Anticancer composition for treating solid tumors and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1 Effects of different doses of MMP on the growth of liver tumors

[0066] Will 2x10 5 A liver cancer tumor cell was subcutaneously injected into the flank of mice, and after 7 days of tumor growth, they were divided into the following 10 groups (6 mice in each group, see Table 1). Group 1 is the control group, groups 2-4 are the MMP-1 treatment group, groups 5-7 are the bromelain treatment group, and groups 8-10 are the MMP-7 treatment group. The drug was injected into the tumor, and the dose was calculated in kilograms of body weight (mg / kg) (see Table 1 for the specific dose), administered once a day for a total of 3 times. The tumor volume was measured on the 15th day after treatment, and the treatment effects of each group were compared (see Table 1). The activity of MMP-1 used is 268U / mg, the activity of bromelain is 800U / mg, and the activity of MMP-7 is 186U / mg.

[0067] Table 1

[0068] Group (n=6) receive treatment Tumor volume (mm 3 )...

Embodiment 2

[0073] Example 2 Effects of different doses of MMP on the growth of rectal tumors

[0074] Will 2x10 5 A rectal cancer cell was subcutaneously injected into the flank of mice, and after 7 days of tumor growth, they were divided into the following 10 groups (6 rats in each group, see Table 2). Group 1 is the control group, groups 2-4 are the MMP-2 treatment group, groups 5-7 are the bromelain treatment group, and groups 8-10 are the MMP-7 treatment group. The drug was injected into the tumor, and the dose was calculated in kilograms of body weight (mg / kg) (see Table 2 for the specific dose), administered once a day for a total of 3 times. The tumor volume was measured on the 15th day after treatment, and the treatment effects of each group were compared (see Table 2). The activity of MMP-2 used is 180U / mg, the activity of bromelain is 800U / mg, and the activity of MMP-7 is 186U / mg.

[0075] Table 2

[0076] Group (n=6) receive treatment Tumor volume (mm 3 )

...

Embodiment 3

[0080] Example 3 Comparison of inhibitory effects of MMP-8 on tumors with different volumes

[0081] Mice of the same gender and similar body weight were divided into 3 groups, and different numbers of lung cancer cells were subcutaneously injected into the quarter ribs of the mice, among which the first group was subcutaneously injected with 2x10 5 Individual tumor cells, group 2 subcutaneously injected 5x10 5 Individual tumor cells, group 3 subcutaneously injected 2x10 6 a tumor cell. After 14 days of tumor growth, the size of the tumor body was measured, and then each group of animals was randomly divided into two groups (n=6), one of which received MMP-8 intratumoral injection, once injected 0.1ml into the tumor, and each ml injection contained 1000UMMP- 8. The other group received the same amount of normal saline. On the 10th day after treatment, the tumor volume was measured again, and the tumor growth inhibition rate was compared (see Table 3). The activity of colla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The application provides an anticancer composition for treating solid tumors, which comprises an anticancer active ingredient and a pharmaceutically acceptable carrier, wherein the anticancer active ingredient is one or more matrix metalloproteinases, preferably One or any combination of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, and MMP-18. The application also provides the use of the anticancer composition in the preparation of medicines for treating solid tumors. The anticancer composition of the present invention is suitable for intratumoral injection or implantation, peritumoral injection or implantation, and intratumoral injection or implantation after cancer surgery. The anticancer composition can be made into various pharmaceutical dosage forms, preferably injection.

Description

technical field [0001] The present application relates to an anticancer composition for treating solid tumors and a method for treating solid tumors, and also relates to the use of the anticancer composition in the preparation of medicines for treating solid tumors. Background technique [0002] Cancer has become the first cause of death in humans, mainly due to uncontrollable metastasis and spread in the late stage. The latter is the leading cause of treatment failure in cancer patients. [0003] The metastasis of cancer is a complex multifactorial process, in which matrix metalloproteinases (MatrixMetalloproteinases, MMPs) play an important role in this process (Kumar A, Collins HM, Scholefield JH, Watson SA: Increased type-IV collagenase (MMP- 2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. Br J Cancer 82:960–965, 2000). MMPs not only mediate the degradation of extracellular matrix (ECM), including the basement membrane, by tumor cells, but a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/48A61P35/00
Inventor 孙娟李学英俞建江姜俊敏
Owner DASEN BIOLOGICAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap